The Braver Wealth Management LLC Has $2,672,000 Position in CVS Health Corporation (CVS)

The Braver Wealth Management LLC Has $2,672,000 Position in CVS Health Corporation (CVS)

Braver Wealth Management LLC raised its stake in CVS Health Corporation (NYSE:CVS) by 7.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,027 shares of the pharmacy operator’s stock after buying an additional 2,091 shares during the period. Braver Wealth Management LLC’s holdings in CVS Health Corporation were worth $2,672,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Bridge Creek Capital Management LLC boosted its stake in CVS Health Corporation by 0.5% in the second quarter. Bridge Creek Capital Management LLC now owns 39,538 shares of the pharmacy operator’s stock valued at $3,785,000 after buying an additional 179 shares during the last quarter. Ngam Advisors L.P. boosted its stake in CVS Health Corporation by 1.9% in the second quarter. Ngam Advisors L.P. now owns 233,294 shares of the pharmacy operator’s stock valued at $22,336,000 after buying an additional 4,315 shares during the last quarter. BP PLC boosted its stake in CVS Health Corporation by 17.9% in the second quarter. BP PLC now owns 138,000 shares of the pharmacy operator’s stock valued at $13,211,000 after buying an additional 21,000 shares during the last quarter. Retirement Systems of Alabama boosted its stake in CVS Health Corporation by 8.7% in the second quarter. Retirement Systems of Alabama now owns 1,043,349 shares of the pharmacy operator’s stock valued at $99,890,000 after buying an additional 83,608 shares during the last quarter. Finally, Veritas Asset Management LLP boosted its stake in CVS Health Corporation by 10.1% in the second quarter. Veritas Asset Management LLP now owns 4,808,477 shares of the pharmacy operator’s stock valued at $460,364,000 after buying an additional 439,848 shares during the last quarter. Hedge funds and other institutional investors own 80.32% of the company’s stock.

Shares of CVS Health Corporation (NYSE:CVS) traded down 0.3233% during mid-day trading on Thursday, hitting $83.2699. The stock had a trading volume of 4,566,558 shares. The firm has a market cap of $88.80 billion, a P/E ratio of 17.8461 and a beta of 0.84. CVS Health Corporation has a 12-month low of $69.30 and a 12-month high of $106.67. The company has a 50 day moving average price of $80.03 and a 200 day moving average price of $87.20.

CVS Health Corporation (NYSE:CVS) last announced its earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.07. The firm had revenue of $44.60 billion for the quarter, compared to the consensus estimate of $45.29 billion. CVS Health Corporation had a return on equity of 17.18% and a net margin of 2.96%. The firm’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.28 EPS. Equities analysts forecast that CVS Health Corporation will post $5.81 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 2nd. Shareholders of record on Tuesday, January 24th will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, January 20th. This represents a $2.00 annualized dividend and a yield of 2.39%. This is an increase from CVS Health Corporation’s previous quarterly dividend of $0.43. CVS Health Corporation’s payout ratio is presently 36.40%.

Several equities research analysts recently weighed in on CVS shares. Mizuho restated a “buy” rating and set a $111.00 target price on shares of CVS Health Corporation in a research note on Friday, September 30th. Leerink Swann reiterated an “outperform” rating and issued a $105.00 price objective (down previously from $110.00) on shares of CVS Health Corporation in a research note on Sunday, October 2nd. Vetr cut CVS Health Corporation from a “strong-buy” rating to a “hold” rating and set a $87.73 price objective for the company. in a research note on Thursday, October 6th. Deutsche Bank AG reiterated a “hold” rating and issued a $99.00 price objective (down previously from $108.00) on shares of CVS Health Corporation in a research note on Tuesday, October 18th. Finally, Credit Suisse Group AG reiterated an “outperform” rating and issued a $110.00 price objective (down previously from $115.00) on shares of CVS Health Corporation in a research note on Tuesday, October 4th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $101.77.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).

Related posts

Leave a Comment